GILDNASDAQ— Gilead Sciences Inc Price & Analysis

Gilead Sciences Inc

HEALTHCARE — DRUG MANUFACTURERS - GENERAL

$151.00

-$0.22-0.15%

Market Cap: $187.51B; Large Cap
P/E Ratio: N/A; Fwd: 15.27
EPS (TTM): $-2.68
Div. Yield: 2.15%

Technical Summary

RSI (14)67.71Neutral

SMA (50)$136.60Bullish

SMA (200)$133.38Bullish

MACD4.3363Bullish

Bollinger$133.32 – $155.37Mid

Stochastic87.35Overbought

Theo Outlook

Gilead Sciences presents a mixed but recovering outlook with a market capitalization of $187.2 billion, a trailing P/E of 15.41, forward P/E of 6.15, negative EPS of -$2.66, and year-over-year quarterly revenue growth of 10.2%. Despite the negative profit margin of -10.6%, the low forward multiple signals potential earnings rebound in its antiviral portfolio. Key catalysts include upcoming dividend payments on September 29, 2026, with a 2.13% yield, analyst target price of $157.41, and strong institutional ownership at 92.4%. Growth drivers center on HIV and hepatitis treatments, supported by 10.2% revenue expansion and analyst ratings showing 21 buy/strong buy versus 7 hold/sell. Risks include regulatory hurdles in drug approvals, competition from generics in antivirals, and macroeconomic pressures on healthcare spending. Mitigations involve Gilead's robust pipeline, 14.6B EBITDA, and diversified revenue from established products like Harvoni, with beta of 0.35 providing relative stability. Analysis generated by HeyTheo AI based on SEC filings, earnings transcripts, and market data.

Analysis generated by HeyTheo AI on Sep 7, 2026.

Company Overview

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.

Fundamental Snapshot

Revenue: $30.46B
EBITDA: $14.60B
Gross Profit: $24.25B
Operating Margin: 33.7%
Profit Margin: -10.6%
ROE: -20.7%
Book Value: $9.53
Beta: 0.34
52-Wk High: $155.38
52-Wk Low: $106.44
Avg Volume: 5.82M
PEG Ratio: 2.01

Frequently Asked Questions

What is Gilead Sciences' business model?

Gilead Sciences develops and commercializes antiviral drugs for HIV, hepatitis B/C, and influenza. It generates revenue primarily through product sales of treatments like Harvoni and Sovaldi, with TTM revenue of $30.5 billion and gross profit of $24.2 billion.

What are Gilead's main revenue sources?

Revenue comes mainly from antiviral pharmaceuticals, with TTM revenue at $30.5 billion and quarterly revenue growth of 10.2% year-over-year. Key products target HIV and hepatitis, supported by a 2.13% dividend yield on $3.22 per share.

What competitive advantages does Gilead have?

Gilead benefits from a strong patent-protected portfolio in antivirals, high institutional ownership of 92.4%, and low beta of 0.35. Its forward P/E of 6.15 and $14.6 billion EBITDA provide pricing power and R&D funding advantages over peers.

What are the key risks for GILD stock?

Risks include patent expirations leading to generic competition, regulatory delays, and negative EPS of -$2.66 with -10.6% profit margin. Macro headwinds like healthcare cost pressures could impact sales, though mitigated by a $157.41 analyst target.

What is the growth outlook for Gilead?

Growth outlook is positive with 10.2% quarterly revenue growth, upcoming September 29, 2026 dividend, and analyst consensus leaning buy. Latest quarter ending June 30, 2026, and forward P/E of 6.15 suggest earnings recovery potential in its core antiviral markets.